Most of what’s written about China in biopharma stops at deal value. We wanted to know what it looks like from the inside: in negotiations, in the boardroom and in how teams are built.
Over the last three months, China came up in conversation after conversation with CBOs, heads of BD and other senior leaders, usually before we asked. This paper draws on 30 of those conversations, alongside the latest deal data, to show what senior leaders are seeing and how they are responding.
Early-Stage BD: What Actually Happens Before the Deal Announcement
Most biopharma BD content focuses on closed deals — the press releases, the headline terms, the conference panels celebrating success.
This report examines what happens before any of that: the operational reality of building and running BD at preclinical to Phase 1 companies, based on confidential interviews with 16 Chief Business Officers across the US and Europe.
It addresses:
How the CBO role has expanded beyond dealmaking
Where deals actually get stuck
What non-BD colleagues consistently misunderstand about timelines, expectations, and what BD can and cannot control
How China has become a competitive pressure point
What the deal environment looks like now
The outlook for the next 12-18 months and what leaders are preparing for
The report includes both a thematic synthesis and an anonymised Q&A addendum with the full interview transcripts.
Volume 2, covering Phase 2-3 through commercial organisations, will be published in January 2026.

